logo
logo
PACB stock ticker logo

Pacific Biosciences of California, Inc.

NASDAQ•PACB
CEO: Mr. Christian O. Henry M.B.A.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2010-10-27
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Contact Information
1305 O’Brien Drive, Menlo Park, CA, 94025, United States
650-521-8000
www.pacb.com
Market Cap
$458.90M
P/E (TTM)
-0.8
30
Dividend Yield
--
52W High
$2.73
52W Low
$0.85
52W Range
36%
Rank67Top 97.6%
1.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$44.65M+0.00%
4-Quarter Trend

EPS

-$0.13+0.00%
4-Quarter Trend

FCF

-$24.93M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Increased 4% Total revenue reached $160.0 M, driven by $11.6 M growth in consumables sales, offsetting instrument revenue decline.
Gross Profit Grew 23% Gross profit improved to $45.8 M, reflecting favorable product mix from higher consumable volumes and lower cost of revenue.
Asset Sale Proceeds Realized Received $48.1 M net cash proceeds from January 2026 disposition of short-read DNA sequencing assets, waiving Apton milestones.
Operating Expenses Reduced R&D expense fell 28% to $97.3 M and SG&A dropped 19% to $141.5 M following 2025 restructuring efforts.

Risk Factors

Continued Significant Operating Losses Operating loss widened 17% to $(553.9) M; expects continued losses, limiting ability to fund long-term operations.
Instrument Sales Declined 18% Instrument revenue dropped $12.0 M due to 61 units sold, reflecting elongated sales cycles and capital funding constraints.
Large Intangible Asset Charges Recorded $359.3 M accelerated amortization of developed technology and $15.0 M IPR&D impairment in 2025.
Cash Position Decreased Cash, equivalents, and investments fell 28% to $279.5 M, primarily due to $111.2 M cash used in operating activities.

Outlook

Accelerate Revio Platform Adoption Focus on accelerating samples onto the Revio platform using SPRQ-Nx chemistry to lower sequencing cost and improve efficiency.
Expand Vega Benchtop Capabilities Plan software improvements for Vega benchtop platform to enable faster run times, broadening market reach and improving economics.
Progress Clinical Strategy Durability Drive sustained utilization of HiFi sequencing by progressing clinical strategy, supporting adoption in laboratory-developed test settings.
Advance Data-Driven Interpretation Leverage HiFi accuracy and growing datasets to support advanced data analysis and AI-assisted interpretation approaches for growth.

Peer Comparison

Revenue (TTM)

IART stock ticker logoIART
$1.64B
+1.5%
VREX stock ticker logoVREX
$854.40M
+4.1%
OFIX stock ticker logoOFIX
$822.31M
+2.9%

Gross Margin (Latest Quarter)

IOVA stock ticker logoIOVA
215.9%
+65.9pp
DNA stock ticker logoDNA
124.4%
-21.7pp
LAB stock ticker logoLAB
83.5%
-3.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
IOVA$1.24B-3.9-54.5%5.3%
BFLY$929.58M-12.1-35.3%6.0%
IART$822.54M-1.6-44.5%20.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.3%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Deep Research

Next earnings:Aug 3, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data